The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Open accessAbstract
BACKGROUND: In a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We conducted a phase 3 study of the efficacy and safety of the combination versus gemcitabine monotherapy in patients with metastatic pancreatic cancer. METHODS: We randomly assigned patients with a Karnofsky performance-status score of 70 or more (on a scale from 0 to 100, with higher scores indicating better performance status) to nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks or gemcitabine monotherapy (1000 mg per square meter) weekly for 7 of 8 weeks (cycle 1) and then on days 1, 8, and 15 every 4 weeks (cycle 2 and subsequent cycles). Patients received the study treatment until disease progression. The primary end point was overall survival; secondary end points were progression-free survival and overall response rate. RESULTS: A total of 861 patients were randomly assigned to nab-paclitaxel plus gemcitabine (431 patients) or gemcitabine (430). The median overall survival was 8.5 months in the nab-paclitaxel-gemcitabine group as compared with 6.7 months in the gemcitabine group (hazard ratio for death, 0.72; 95% confidence interval [CI], 0.62 to 0.83; P<0.001). The survival rate was 35% in the nab-paclitaxel-gemcitabine group versus 22% in the gemcitabine group at 1 year, and 9% versus 4% at 2 years. The median progression-free survival was 5.5 months in the nab-paclitaxel-gemcitabine group, as compared with 3.7 months in the gemcitabine group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.58 to 0.82; P<0.001); the response rate according to independent review was 23% versus 7% in the two groups (P<0.001). The most common adverse events of grade 3 or higher were neutropenia (38% in the nab-paclitaxel-gemcitabine group vs. 27% in the gemcitabine group), fatigue (17% vs. 7%), and neuropathy (17% vs. 1%). Febrile neutropenia occurred in 3% versus 1% of the patients in the two groups. In the nab-paclitaxel-gemcitabine group, neuropathy of grade 3 or higher improved to grade 1 or lower in a median of 29 days. CONCLUSIONS: In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased. (Funded by Celgene; ClinicalTrials.gov number, NCT00844649.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most chemotherapy 5-7, targeted therapy 8, and immunotherapy 9-11 are ineffective because most patients are already in the progressive stage with local invasion and distant metastases at the detection time 12,13.”
From Artificial intelligence in pancreatic cancer (2022) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“two new combination regimens have emerged as the first-line therapy in patients with advanced PDAC. The first is a combination of 5-fluorouracil (5-FU), leucovorin, irinotecan and oxaliplatin, which carries the acronym FOLFIRINOX. The second is the combination of gemcitabine and an albumin nanoparticle conjugate of paclitaxel (nab-paclitaxel)8,9.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [9]
In the citing paper
“Polychemotherapy, either with 5-fluorouracil (5-FU), irinotecan and oxaliplatin in combination with folinic acid (FOLFIRINOX), or with gemcitabine and nab-paclitaxel (GnP), is considered the standard of care for patients suffering from metastatic PDAC (mPDAC)3,4.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [3]
In the citing paper
“However, less than half of all patients are responsive to the therapy, and patients who do not respond (NR patients) suffer from pain and eventually die within weeks3.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [3]
In the citing paper
“Less than half of all patients respond to the primary treatment for PDAC, chemotherapy3,4”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [3]
In the citing paper
“patients who do not respond (NR patients) suffer from pain and eventually die within weeks3.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Self-citationMoore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Self-citationGradishar, W. J., Tjulandin, S., Davidson, N. G. P., Shaw, H., Desai, N. P., Bhar, P., Hawkins, M., & O’Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,159
Self-citationHoff, D. D. V., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., Korn, R. L., Desai, N. P., Trieu, V. N., Iglesias, J. L. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5742 · Cited by 1,040
Self-citationKindler, H. L., Niedzwiecki, D., Hollis, D. R., Sutherland, S., Schrag, D., Hurwitz, H. I., Innocenti, F., Mulcahy, M. F., O'Reilly, E. M., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 848
Cunningham, D., Chau, I., Stocken, D. D., Valle, J. W., Smith, D. B., Steward, W. P., Harper, P., Dunn, J., Smith, C. T., West, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2446 · Cited by 822
Chauffert, B., Mornex, F., Bonnetain, F., Rougier, P. R., Mariette, C., Bouché, O., Bosset, J.-F., Aparicio, T., Mineur, L., Azzedine, A., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn281 · Cited by 696
Philip, P. A., Benedetti, J., Corless, C. L., Wong, R., O'Reilly, E. M., Flynn, P. J., Rowland, K. M., Atkins, J. N., Mirtsching, B. C., Rivkin, S. E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7550 · Cited by 643
Cited by
Sorted by citations
Items 601–700 of 1,022
Multifunctionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cells
Trabulo, S. M. D., Aires, A., Aicher, A., Heeschen, C., & Cortajarena, A. L. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.01.035 · Cited by 87
Metabolic Dependencies in Pancreatic Cancer
Gohar, A. V., Zarei, M., Brody, J. R., & Winter, J. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00617 · Cited by 87
miRNAs in pancreatic cancer: Therapeutic potential, delivery challenges and strategies
Chitkara, D., Mittal, A., & Mahato, R. I. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.006 · Cited by 86
Tremelimumab: research and clinical development
Ibarrondo, F. J., Comin-Anduix, B., & Escuin-Ordinas, H. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s65802 · Cited by 86
Dithiocarbazate-Copper Complexes for Bioimaging and Treatment of Pancreatic Cancer
Gou, Y., Chen, M., Li, S., Deng, J., Li, J., Fang, G., Yang, F., & Huang, G. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01936 · Cited by 86
Li, Q., Feng, Z., Miao, R., Liu, X., Liu, C., & Liu, Z. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02478-x · Cited by 86
Enhanced effect of autologous EVs delivering paclitaxel in pancreatic cancer
Faruque, H. A., Choi, E., Kim, J., & Kim, E. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.012 · Cited by 86
Recent advances in pancreatic cancer: biology, treatment, and prevention
Singh, D. K., Upadhyay, G., Srivastava, R. K., & Shankar, S. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.04.003 · Cited by 85
Yabar, C. S., & Winter, J. M. (2016) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.04.003 · Cited by 85
Targeted Therapies for Pancreatic Cancer
Amanam, I. U., & Chung, V. M. (2018) · Cancers · doi:10.3390/cancers10020036 · Cited by 85
Miyasaka, Y., Ohtsuka, T., Kimura, R., Matsuda, R., Mori, Y., Nakata, K., Kakihara, D., Fujimori, N., Ohno, T., Oda, Y., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07309-8 · Cited by 85
Phillips, C. M., Parmar, A., Guo, H., Schwartz, D., Isaranuwatchai, W., Beca, J. M., Dai, W. F., Arias, J., Gavura, S., & Chan, K. (2020) · Cancer · doi:10.1002/cncr.32697 · Cited by 85
Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies
Reyes‐Castellanos, G., Masoud, R., & Carrier, A. (2020) · Biomedicines · doi:10.3390/biomedicines8080270 · Cited by 85
Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?
Baer, R., Cintas, C., Therville, N., & Guillermet‐Guibert, J. (2015) · Advances in Biological Regulation · doi:10.1016/j.jbior.2015.05.001 · Cited by 85
Pancreatic cancer survival analysis defines a signature that predicts outcome
Raman, P., Maddipati, R., Lim, K., & Tözeren, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201751 · Cited by 84
Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer
Joice, G. A., Bivalacqua, T. J., & Kates, M. R. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0220-4 · Cited by 84
Truty, M. J., Colglazier, J. J., Mendes, B. C., Nagorney, D. M., Bower, T. C., Smoot, R. L., DeMartino, R. R., Cleary, S. P., Oderich, G. S., & Kendrick, M. L. (2020) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2020.05.005 · Cited by 84
Clinical Impact of Molecular Subtyping of Pancreatic Cancer
Zhou, X., Hu, K., Bailey, P. J., Springfeld, C., Roth, S., Kurilov, R., Brors, B., Gress, T. M., Buchholz, M., An, J., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.743908 · Cited by 84
Pietrasz, D., Marthey, L., Wagner, M., Blanc, J., Laurent, C., Turrini, O., Raoul, J., Terrebonne, É., Hentic, O., Trouilloud, I., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4783-x · Cited by 84
Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer
Imaoka, H., Mizuno, N., Hara, K., Hijioka, S., Tajika, M., Tanaka, T., Ishihara, M., Yogi, T., Tsutsumi, H., Fujiyoshi, T., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000446 · Cited by 84
Bijlsma, M. F., & van Laarhoven, H. W. M. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9541-1 · Cited by 84
Marinova, M., Rauch, M., Mücke, M., Rolke, R., Gonzalez-Carmona, M. A., Henseler, J., Cuhls, H., Radbruch, L., Strassburg, C. P., Zhang, L., et al. (2016) · European Radiology · doi:10.1007/s00330-016-4239-0 · Cited by 84
Clinically Meaningful Use of Blood Tumor Markers in Oncology
Holdenrieder, S., Pagliaro, L. C., Morgenstern, D. E., & Dayyani, F. (2016) · BioMed Research International · doi:10.1155/2016/9795269 · Cited by 84
Immunotherapy in pancreatic cancer treatment: a new frontier
Thind, K., Padrnos, L. J., Ramanathan, R. K., & Borad, M. J. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16667909 · Cited by 83
Self-citationKim, S. S. Y., Signorovitch, J., Yang, H., Patterson‐Lomba, O., Xiang, C. Q., Ung, B. L., Parisi, M., & Marshall, J. L. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0784-z · Cited by 83
Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives
Martini, V., Timme‐Bronsert, S., Fichtner‐Feigl, S., Hoeppner, J., & Kulemann, B. (2019) · Cancers · doi:10.3390/cancers11111659 · Cited by 83
Yap, T. A., Vieito, M., Baldini, C., Sepúlveda-Sánchez, J. M., Kondo, S., Simonelli, M., Cosman, R., van der Westhuizen, A., Atkinson, V. G., Carpentier, A. F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1504 · Cited by 83
Zhang, X., Lao, M., Xu, J., Duan, Y., Yang, H., Li, M., Ying, H., He, L., Sun, K., Guo, C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003982 · Cited by 83
Hank, T. P., Klaiber, U., Hinz, U., Schütte, D., Leonhardt, C.-S., Bergmann, F., Hackert, T., Jäger, D., Büchler, M. W., & Strobel, O. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005481 · Cited by 83
Yu, X., Pu, X., Xie, C. L., Song, Y., He, H., Li, H., Lu, W., Fu, D., Jin, C., & Yang, D. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s93835 · Cited by 83
Management of borderline and locally advanced pancreatic cancer: Where do we stand?
He, J. P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i9.2255 · Cited by 83
Pettazzoni, P., Viale, A., Shah, P. K., Carugo, A., Ying, H., Wang, H., Genovese, G., Seth, S., Minelli, R., Green, T., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1854 · Cited by 83
Bachet, J., Gay, F., Maréchal, R., Galais, M., Adenis, A., Salako, D., Cros, J. F., Demetter, P., Svrcek, M., Bardier–Dupas, A., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000394 · Cited by 83
Hu, Z. I., Bendell, J. C., Bullock, A., LoConte, N. K., Hatoum, H., Ritch, P., Hool, H., Leach, J. W., Sanchez, J., Sohal, D. P. S., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2425 · Cited by 82
Acetylation regulates ribonucleotide reductase activity and cancer cell growth
Chen, G., Luo, Y., Warncke, K., Sun, Y., Yu, D. S., Fu, H., Behera, M., Ramalingam, S. S., Doetsch, P. W., Duong, D. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11214-9 · Cited by 82
Biomarkers and Targeted Therapy in Pancreatic Cancer
Karandish, F., & Mallik, S. (2016) · Biomarkers in Cancer · doi:10.4137/bic.s34414 · Cited by 82
Musher, B., Rowinsky, E. K., Smaglo, B. G., Abidi, W. M., Othman, M. O., Patel, K., Jawaid, S. A., Jing, J. M., Brisco, A., Leen, A. M., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00079-2 · Cited by 82
Sasaki, Y., Nishina, T., Yasui, H., Goto, M., Muro, K., Tsuji, A., Koizumi, W., Toh, Y., Hara, T., & Miyata, Y. (2014) · Cancer Science · doi:10.1111/cas.12419 · Cited by 82
Pancreatic stellate cells: Aiding and abetting pancreatic cancer progression
Pothula, S. P., Pirola, R. C., Wilson, J. S., & Apte, M. V. (2020) · Pancreatology · doi:10.1016/j.pan.2020.01.003 · Cited by 82
Khushman, M. M., Dempsey, N. G., Maldonado, J. C., Loaiza‐Bonilla, A., Velez, M., Carcas, L., Dammrich, D., Hurtado-Cordovi, J. M., Parajuli, R., Pollack, T., et al. (2015) · Pancreatology · doi:10.1016/j.pan.2015.08.010 · Cited by 81
Organoid models for translational pancreatic cancer research
Tiriac, H., Plenker, D., Baker, L. A., & Tuveson, D. A. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.02.003 · Cited by 81
Raveendran, R., Bhuvaneshwar, G. S., & Sharma, C. P. (2015) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2015.11.017 · Cited by 81
Saad, E. D., & Buyse, M. E. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv562 · Cited by 81
nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
Soliman, H. H. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s122974 · Cited by 81
Current and future biomarkers for pancreatic adenocarcinoma
Loosen, S. H., Neumann, U. P., Trautwein, C., Roderburg, C., & Luedde, T. (2017) · Tumor Biology · doi:10.1177/1010428317692231 · Cited by 81
Inhibition of ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic cancer
Whatcott, C. J., Ng, S., Barrett, M. T., Hostetter, G. H., Hoff, D. D. V., & Han, H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183871 · Cited by 81
Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer
Chien, W., Sun, Q.-Y., Lee, K. L., Ding, L.-W., Wuensche, P., Torres-Fernandez, L. A., Tan, S. Z., Tokatly, I., Zaiden, N., Poellinger, L., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.01.002 · Cited by 80
Lakdawalla, D., Shafrin, J. T., Hou, N., Peneva, D., Vine, S. M., Park, J., Zhang, J., Brookmeyer, R., & Figlin, R. A. (2017) · Value in Health · doi:10.1016/j.jval.2017.04.003 · Cited by 80
Xin, X., Kumar, V., Lin, F., Kumar, V., Bhattarai, R. S., Bhatt, V. R., Tan, C., & Mahato, R. I. (2020) · Science Advances · doi:10.1126/sciadv.abd6764 · Cited by 80
Exploiting pancreatic cancer metabolism: challenges and opportunities
Santis, M. C. D., Bockorny, B., Hirsch, E., Cappello, P., & Martini, M. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.03.008 · Cited by 85
Systematic review of irreversible electroporation in the treatment of advanced pancreatic cancer
Moir, J., White, S., French, J., Littler, P., & Manas, D. (2014) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2014.08.480 · Cited by 80
Targeting Cancer Stem Cells for Chemoprevention of Pancreatic Cancer
Subramaniam, D., Kaushik, G., Dandawate, P. R., & Anant, S. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170127095832 · Cited by 80
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients
Laquente, B., Lopez-Martin, J. A., Richards, D., Illerhaus, G., Chang, D. Z., Kim, G., Stella, P. J., Richel, D. J., Szcylik, C., Cascinu, S., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3131-x · Cited by 80
iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer
Lo, J. H.-J., Hao, L., Muzumdar, M. D., Raghavan, S., Kwon, E. J., Pulver, E. M., Hsu, F., Aguirre, A. J., Wolpin, B. M., Fuchs, C. S., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1090 · Cited by 80
Seufferlein, T. T. W., Hammel, P. R., Delpéro, J., Macarulla, T. M., Pfeiffer, P., Prager, G. W., Reni, M., Falconi, M., Philip, P. A., & Cutsem, E. V. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.05.007 · Cited by 80
Self-citationPacheco-Barcía, V., Solís, R. M., France, T., Asselah, J., Donnay, O., Zogopoulos, G., Bouganim, N., Guo, K., Rogado, J., Martín, E., et al. (2019) · Pancreatology · doi:10.1016/j.pan.2019.12.010 · Cited by 79
Molecular mediators of peritoneal metastasis in pancreatic cancer
Avula, L. R., Hagerty, B. L., & Alewine, C. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09924-4 · Cited by 79
Chen, Z., Zhang, S., Han, N., Jiang, J., Xu, Y., Ma, D., Lu, L., Guo, X., Qiu, M. R., Huang, Q., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691605 · Cited by 79
Ashrafizadeh, M., Zhang, W., Zou, R., Sethi, G., Klionsky, D. J., & Zhang, X. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106822 · Cited by 79
Li, Y., Tang, S., Shi, X., Lv, J., Wu, X., Zhang, Y., Wang, H., He, J., Zhu, Y., Ju, Y., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101162 · Cited by 79
Ludmir, E. B., Sherry, A. D., Fellman, B. M., Liu, S., Bathala, T. K., Haymaker, C., Medina-Rosales, M. N., Reuben, A., Holliday, E. B., Smith, G. L., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00081 · Cited by 80
Nanomedicines Targeting the Tumor Microenvironment
Tong, R., & Langer, R. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000123 · Cited by 79
Damhofer, H., Ebbing, E. A., Steins, A., Welling, L., Tol, J. A. M. G., Krishnadath, K. K., van Leusden, T., van de Vijver, M. J., Besselink, M. G., Busch, O. R., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0469-1 · Cited by 79
Sho, M., Murakami, Y., Motoi, F., Satoi, S., Matsumoto, I., Kawai, M., Honda, G., Uemura, K., Yanagimoto, H., Kurata, M., et al. (2014) · Journal of Gastroenterology · doi:10.1007/s00535-014-1005-4 · Cited by 79
Vendrely, V., Peuchant, E., Buscail, É., Moranvillier, I., Rousseau, B., Bedel, A., Brillac, A., de Verneuil, H., Moreau‐Gaudry, F., & Dabernat, S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.002 · Cited by 79
Lowery, M. A., Yu, K. H., Kelsen, D. P., Harding, J. J., Bomalaski, J. S., Glassman, D. C., Covington, C. M., Brenner, R., Hollywood, E. M., Barba, A., et al. (2017) · Cancer · doi:10.1002/cncr.30897 · Cited by 79
Satoi, S., Yamamoto, T., Yamaki, S., Sakaguchi, T., & Sekimoto, M. (2019) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12295 · Cited by 79
Smarter drugs emerging in pancreatic cancer therapy
Kleger, A., Perkhofer, L., & Seufferlein, T. T. W. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu013 · Cited by 78
Ettrich, T. J., Berger, A. W., Perkhofer, L., Daum, S., König, A. O., Dickhut, A., Wittel, U. A., Wille, K., Geißler, M., Algül, H., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-5183-y · Cited by 78
Broekgaarden, M., Anbil, S. R., Bulin, A., Obaid, G., Mai, Z., Baglo, Y., Rizvi, I., & Hasan, T. G. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119421 · Cited by 78
Dotan, E., Cardin, D. B., Lenz, H., Messersmith, W. A., O’Neil, B. H., Cohen, S. J., Denlinger, C. S., Shahda, S., Astsaturov, I. A., Kapoun, A. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0489 · Cited by 78
Meng, L., Shi, G., Ge, W., Huang, X., Chen, Q., Yuan, H., Wu, P., Lu, Y., Shen, P., Zhang, Y., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.08.001 · Cited by 78
Huerta, M., Roselló, S., Sabater-Orti, L., Ferrer, A., Tarazona, N., Roda, D., Gambardella, V., Alfaro‐Cervelló, C., Garcés‐Albir, M., Cervantes, A. M. R., et al. (2021) · Cancers · doi:10.3390/cancers13050994 · Cited by 78
Liu, H., Shi, Y., & Qian, F. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.012 · Cited by 78
Nel, A. E., Mei, K., Liao, Y., & Liu, X. (2022) · ACS Nano · doi:10.1021/acsnano.2c01252 · Cited by 81
CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer
Jacoberger-Foissac, C., Cousineau, I., Barèche, Y., Allard, D., Chrobák, P., Allard, B., Pommey, S., Messaoudi, N., McNicoll, Y., Soucy, G., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0260 · Cited by 78
Yarchoan, M. M., Myzak, M. C., Johnson, B. A., Jesus‐Acosta, A. D., Le, D. T., Jaffee, E. M., Azad, N. S., Donehower, R. C., Zheng, L., Oberstein, P. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17237 · Cited by 78
Self-citationTriggered release of paclitaxel from magnetic solid lipid nanoparticles by magnetic hyperthermia
Oliveira, R. R., Carrião, M. S., Pacheco, M. T., Branquinho, L. C., de Souza, A. L. R., Bakuzis, A. F., & Lima, E. M. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2018.07.011 · Cited by 78
Jameson, G., Borazanci, E. H., Babiker, H. M., Poplin, E. A., Niewiarowska, A. A., Gordon, M. S., Barrett, M. T., Rosenthal, A., Stoll-D'Astice, A. C., Crowley, J. J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3394 · Cited by 78
Self-citationGarcia, P. L., Miller, A. L., & Yoon, K. J. (2020) · Cancers · doi:10.3390/cancers12051327 · Cited by 77
Sinn, M., Sinn, B. V., Striefler, J. K., Lindner, J., Stieler, J., Lohneis, P., Bischoff, S., Bläker, H., Pelzer, U., Bahra, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu084 · Cited by 77
ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications
Armstrong, S. A., Schultz, C. W., Azimi-Sadjadi, A., Brody, J. R., & Pishvaian, M. J. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0208 · Cited by 78
Abbas, A. I. A., Zenati, M. S., Reiser, C. J., Hamad, A. B., Jung, J. P., Zureikat, A. H., Zeh, H. J., & Hogg, M. E. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-019-08156-3 · Cited by 77
The Role of Imaging in Current Treatment Strategies for Pancreatic Adenocarcinoma
Rhee, H., & Park, M. (2020) · Korean Journal of Radiology · doi:10.3348/kjr.2019.0862 · Cited by 77
Tarannum, M., & Vivero-Escoto, J. L. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114357 · Cited by 77
Kim, S., Leem, G., Choi, J., Koh, Y., Lee, S., Nam, S., Kim, J. S., Park, C. H., Hwang, H. K., Min, K. I., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01287-7 · Cited by 81
Assénat, E., Azria, D., Mollévi, C., Guimbaud, R., Tubiana-Mathieu, N., Smith, D. M., Delord, J., Samalin, E., Portales, F., Larbouret, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3473 · Cited by 77
Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer
McCarroll, J. A., Teo, J., Boyer, C. A., Goldstein, D., Kavallaris, M., & Phillips, P. A. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00002 · Cited by 77
Self-citationNakai, Y., Isayama, H., Kogure, H., Hamada, T., Togawa, O., Ito, Y., Matsubara, S., Arizumi, T., Yagioka, H., Mizuno, S., et al. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12602 · Cited by 77
Qiu, J., Yang, G., Feng, M., Zheng, S., Cao, Z., You, L., Zheng, L., Zhang, T., & Zhao, Y. (2018) · Molecular Cancer · doi:10.1186/s12943-017-0755-z · Cited by 77
Kaissis, G., Ziegelmayer, S., Lohöfer, F., Steiger, K., Algül, H., Muckenhuber, A., Yen, H.-Y., Rummeny, E., Friess, H., Schmid, R., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0218642 · Cited by 76
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients
Mohindroo, C., Hasanov, M., Rogers, J. E., Dong, W., Prakash, L. R., Baydogan, S., Mizrahi, J. D., Overman, M. J., Varadhachary, G. R., Wolff, R. A., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3870 · Cited by 76
MicroRNA Targeted Therapeutic Approach for Pancreatic Cancer
Li, Y., & Sarkar, F. H. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.15017 · Cited by 76
Lee, H. S., Park, S. B., Kim, S. A., Kwon, S. K., Cha, H., Lee, D. Y., Ro, S., Cho, J. M., & Song, S. Y. (2017) · Scientific Reports · doi:10.1038/srep41615 · Cited by 76
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer
Spano, C., Grisendi, G., Golinelli, G., Rossignoli, F., Prapa, M., Bestagno, M., Candini, O., Petrachi, T., Recchia, A., Miselli, F., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37433-6 · Cited by 76
Albumin-Bound Paclitaxel plus Gemcitabine in Pancreatic Cancer
Hoff, D. D. V., Goldstein, D., & Renschler, M. F. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1314761 · Cited by 76
Self-citationDalgleish, A. G., Stebbing, J., Adamson, D. J., Arif, S. S., Bidoli, P., Chang, D., Cheeseman, S., Diaz-Beveridge, R., Fernandez-Martos, C., Glynne-Jones, R., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.271 · Cited by 75
Fokas, E., O’Neill, E., Gordon-Weeks, A. N., Mukherjee, S., McKenna, W. G., & Muschel, R. J. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.12.001 · Cited by 75
BRCA mutated pancreatic cancer: A change is coming
Rosen, M. N., Goodwin, R. A., & Vickers, M. M. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i17.1943 · Cited by 75
Chen, H., Guo, Q., Chu, Y., Li, C., Zhang, Y., Liu, P., Zhao, Z., Wang, Y., Luo, Y., Zhou, Z., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121599 · Cited by 75
Metadata
- Authors
- Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., Harris, M., Reni, M., Dowden, S., Laheru, D., Bahary, N., Ramanathan, R. K., Tabernero, J., Hidalgo, M., Goldstein, D., Van Cutsem, E., Wei, X., Iglesias, J., & Renschler, M. F.
- Affiliations
- University of Washington (US)
- Tennessee Oncology (US)
- Princess Margaret Cancer Centre (CA)
- Russian Cancer Research Center NN Blokhin (RU)
- Translational Genomics Research Institute (US)
- Georgia Cancer Specialists (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- University of Pittsburgh Medical Center (US)
- Universitat Autònoma de Barcelona (ES)
- Prince of Wales Hospital (AU)
- Celgene (United States) (US)
- Bionomics (Australia) (AU)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-31
- Volume
- 369
- Issue
- 18
- Pages
- 1691-1703
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4631139
- OpenAlex
- W2165480504
- Cited by
- 6,712
- References
- 23
- Citations by year
- 2026: 403 · 2025: 491 · 2024: 537 · 2023: 607 · 2022: 614 · 2021: 695 · 2020: 631 · 2019: 531 · 2018: 548 · 2017: 512 · 2016: 423 · 2015: 424 · 2014: 271 · 2013: 15
- FWCI
- 200.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic cancer, metastatic pancreatic cancer, nab-paclitaxel, gemcitabine, combination chemotherapy, gemcitabine monotherapy, overall survival, progression-free survival, overall response rate, treatment safety, adverse events, chemotherapy schedule, Karnofsky performance status
- MeSH terms
- Gemcitabine, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Albumins, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Female, Humans, Male, Middle Aged, Nervous System Diseases, Neutropenia, Pancreatic Neoplasms, Paclitaxel, Disease-Free Survival, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
